- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
AstraZeneca to stop development of olaparib for ovarian cancer
Tuesday, December 20 2011 | Comments
What's This?
AstraZeneca Plc will not advance olaparib into Phase III development for the maintenance treatment of serous ovarian cancer. The company made its decision after reviewing data from an interim analysis of a Phase II study of the drug. The study findings indicated that "the previously reported progression-free survival benefit is unlikely to translate into an overall survival benefit," which AstraZeneca described as the definitive measure of patient benefit in ovarian cancer.
Moreover, attempts to identify a suitable tablet dose for use in Phase III trials have not been successful, the company added. No new safety concerns were identified for patients who were treated with olaparib, an oral poly ADP-ribose polymerase inhibitor.
AstraZeneca said the firm would record a $285 million pretax charge as a result of its decision to terminate further development of olaparib in this indication.
Comments
Be the first to write a comment for this article!
You must be logged in to post a comment.
- Researchers evaluate predictors of re-excision, residual disease in women with close, positive margins following partial mastectomy
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Men with biopsy Gleason score 7, tertiary grade 5 disease face similar risk of PSA recurrence as men with higher Gleason score disease, study data suggest
- PSA screening controversy increases with release of mortality studies with conflicting results, modest benefits
- Serial prostate biopsies linked to increased risk of erectile dysfunction, study shows
- Radiation therapy for prostate cancer raises bladder, rectal cancer risk, study indicates
- Study supports use of adenoma detection rate as quality indicator for colonoscopy screening
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- Serial prostate biopsies linked to increased risk of erectile dysfunction, study shows
